Pliant Therapeutics (PLRX)

Executive Summary

Pliant Therapeutics (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases by targeting integrins and the TGF-β pathway. Its lead candidate, bexotegrast (PLN-74809), is a dual-selective integrin inhibitor being evaluated for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast has completed multiple Phase 2 trials, showing encouraging efficacy and safety data. The company is advancing bexotegrast toward pivotal trials, with potential to address significant unmet needs in IPF and PSC, markets with limited treatment options. Additionally, Pliant is developing PLN-101095, a TNF-like ligand inhibitor, in a Phase 1 study for metastatic solid tumors in combination with pembrolizumab. With a focused pipeline and strong scientific foundation, Pliant represents a high-risk, high-reward opportunity in fibrotic disease therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 trial for bexotegrast in IPF70% success
• H2 2026Topline results from bexotegrast Phase 2b/3 dose-ranging study in IPF60% success
• Q3 2026Interim data from Phase 1 trial of PLN-101095 plus pembrolizumab in solid tumors50% success